BRBernhard Richter

Bernhard Richter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernhard Richter has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Johann Wojta

    Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria

    18 shared publications
  • Alexander Niessner

    Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

    12 shared publications
  • Gerlinde Zorn

    Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

    12 shared publications
  • Marianne Gwechenberger

    Divison of Cardiology; Department of Internal Medicine II; Medical University of Vienna; Vienna Austria

    12 shared publications
  • Martin Hülsmann

    Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

    12 shared publications
  • Kurt Huber

    Wilhelminen Hosp, Dept Cardiol & Emergency Med, Vienna, Austria

    10 shared publications

Latest Publications

  • Open Access

    Limb Ischemia-Related Interventions and 30-Day Mortality After Femoro-Femoral VA-ECMO: A Pre/Post Implementation-Era Comparison

    by Robert Zilberszac, Andreas Gleiss, Bernhard Richter, Anne-Kristin Schäfer, Julia Riebandt, Patrick Haider, Thomas M. Hofbauer, Max Lenz, Georg Gelbenegger, Yalong Sun, et al.

    Background/Objectives: Femoro-femoral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is associated with limb ischemic complications. Routine near-infrared spectroscopy (NIRS) monitoring and a more standardized distal perfusion strategy were introduced at our institution in 2016. We compared ischemia-related interventions, amputations, and early mortality between the treatment eras. Methods: Consecutive patients undergoing femoro-femoral VA-ECMO from 2012 to 2024 were analyzed retrospectively and stratified by VA-ECMO initiation before 2016 or from 2016 onward. The primary endpoint was a peripheral ischemic vascular complication requiring surgical or interventional therapy; an inclusive sensitivity definition additionally incorporated four clinically plausible but less certain events. Period-specific rates were estimated using Poisson regression adjusted for baseline distal perfusion cannula (DPC) status and extracorporeal cardiopulmonary resuscitation (eCPR). Results: The analytic cohort comprised 270 patients (45 pre-2016 and 225 post-2016). The primary endpoint occurred in 50 patients (18.5%, 95% confidence interval (CI) 14.1–23.7): 3/45 (6.7%, 95% CI 1.4–18.3) before 2016 and 47/225 (20.9%, 95% CI 15.8–26.8) thereafter. Adjusted rates were 4.6% (95% CI 1.0–20.5) and 18.9% (95% CI 13.6–26.3), with an adjusted risk ratio of 4.11 (95% CI 1.06–17.93). The inclusive sensitivity analysis yielded similar estimates (adjusted risk ratio 3.31, 95% CI 1.05–11.47). Five patients underwent lower-limb amputation (1/45 pre-2016 and 4/225 post-2016). Kaplan–Meier 30-day mortality estimates were 56.8% overall (95% CI 50.8–62.9), 58.9% pre-2016 (95% CI 44.9–73.5), and 56.4% post-2016 (95% CI 49.9–63.1). Conclusions: Ischemia-related interventions were more frequently recorded after 2016, while amputations remained rare and 30-day mortality was similar. Because monitoring, DPC practice, and other aspects of care changed concurrently, and NIRS was used without a standardized trigger algorithm, the reasons for the observed era difference cannot be determined. The findings are exploratory and do not establish causal effects of NIRS or DPC use.

  • Open Access

    Nonlinear Associations of Uric Acid and Mitochondrial DNA with Mortality in Critically Ill Patients

    by Max Lenz, Robert Zilberszac, Christian Hengstenberg, Johann Wojta, Bernhard Richter, Gottfried Heinz, Konstantin A. Krychtiuk, Walter S. Speidl

    Background: Mitochondrial DNA (mtDNA) has strong pro-inflammatory potential and was found to be associated with mortality in critically ill patients. The purine bases from circulating cell-free DNA, including mtDNA, are catabolised into uric acid, contributing to elevated systemic levels. However, the prognostic value of uric acid in unselected critically ill intensive care unit (ICU) patients remains unclear. We aimed to investigate the association between uric acid levels at admission and 30-day mortality, assess its correlation with mtDNA, and examine prognostic relevance based on the primary cause of admission. Methods: This prospective single-centre study included 226 patients admitted to a tertiary care ICU. Uric acid and mtDNA levels were assessed at admission. Survival analyses were performed in the overall cohort and in subgroups stratified by primary diagnosis. Results: Uric acid showed a U-shaped association with 30-day mortality, with both low and high levels linked to reduced survival. In multivariate analysis, the 4th quartile of uric acid remained associated with adverse outcomes, independent of sex, vasopressors, mechanical ventilation, and creatinine (HR 2.549, 95% CI: 1.310–4.958, p = 0.006). A modest correlation was observed between uric acid and mtDNA (r = 0.214, p = 0.020). However, prognostic relevance varied by diagnosis. While uric acid predicted mortality in patients following cardiac arrest (p = 0.017), mtDNA was found to bear prognostic value in cardiogenic shock and decompensated heart failure (p = 0.009). Conclusions: Uric acid was independently associated with mortality in critically ill patients, with both low and high levels carrying prognostic value. Its predictive capabilities differed from mtDNA but showed partial overlap. However, both markers exhibited varying prognostic performance depending on the primary cause of admission.


  • Open Access

    Soluble urokinase plasminogen activator receptor predicts survival and hospitalization for heart failure in elective cardiac surgery

    by L Koller, E Steinacher, F Hofer, N Kazem, G Laufer, T Fleck, J Wojta, B Steinlechner, B Richter, C Hengstenberg, et al.

    Aims: The study investigated the prognostic value of soluble urokinase plasminogen activator receptor (suPAR) patients undergoing cardiac surgery and calculated a simplified biomarker score comprising suPAR, N-terminal pro B-type natriuretic peptide (NT-proBNP) and age. Methods and results: Biomarkers were assessed in a cohort of 478 patients undergoing elective cardiac surgery. After a median follow-up of 4.2 years a total of 72 (15.1%) patients died. SuPAR, NT-proBNP and age were independent prognosticators of mortality in a multivariable Cox regression model after adjustment for EuroScoreII. We then calculated a simplified biomarker score comprising age, suPAR and NT-proBNP, which had a superior prognostic value compared to EuroScoreII (Harrel's C of 0.76 vs 0.72; P for difference = 0.02). Besides long-term mortality, the biomarker score had an excellent performance predicting one-year mortality and hospitalization due to heart failure. Conclusion: The biomarker suPAR and NT-proBNP were strongly and independently associated with mortality in patients undergoing cardiac surgery. A simplified biomarker score comprising only 3 variables (age, suPAR and NT-proBNP) performed better than the established EuroScoreII with respect to intermediate and long-term outcome as well as hospitalization due to heart failure. As such, integration of established and upcoming biomarkers in clinical practice may provide improved decision support in cardiac surgery. Funding Acknowledgement: Type of funding sources: None.

  • The “Pectoral-Gap Phenomenon”: A Hypothesis on Origin and Mechanism

    by Sebastian Schnaubelt, Georgios Neophytou, Bernhard Richter, Hans Domanovits, Alexander Niessner, Patrick Sulzgruber


  • Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure

    by Lorenz Koller, Stefan Stojkovic, Bernhard Richter, Patrick Sulzgruber, Christos Potolidis, Florian Liebhart, Deddo Mörtl, Rudolf Berger, Georg Goliasch, Johann Wojta, et al.


  • The impact of CD4+CD28null T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure

    by Patrick Sulzgruber, Lorenz Koller, Max-Paul Winter, Bernhard Richter, Steffen Blum, Magdalena Korpak, Martin Hülsmann, Georg Goliasch, Johann Wojta, Alexander Niessner

    Atrial fibrillation (AF) represents the most common cardiac arrhythmia. Especially in patients with chronic heart failure (CHF) the development of AF represents a severe complication resulting in haemodynamic deterioration. While pro-inflammatory cytokines proved to have a pivotal role in the development and progression of both AF and CHF, less attention has been paid to the cellular immunity. Therefore we prospectively enrolled 112 patients with CHF and performed fluorescein-activated cell sorting (FACS). Patients were stratified in two subgroups according to patients presenting with AF (n=56) and patients free of AF (n=56). Comparing AF to non-AF patients we found a significantly lower fraction of regulatory T cells (p+ cells (p=0.007) and more specifically a significantly higher number of cytotoxic T cells characterised by the loss of CD28 within CD4 T cells (CD4+CD28null; p=0.035) in individuals with AF. After a mean follow-up time of 4.5 years 32 (28.6 %) patients died due to cardiovascular causes. CD4+CD28null cells were significantly associated with cardiovascular mortality in patients presenting with AF, with an adjusted HR per one standard deviation (1-SD) of 1.59 (95 % CI 1.13–2.24; p=0.008), but not in patients free of AF with an adjusted HR per 1-SD of 1.27 (95 % CI 0.86–1.87; p=0.216). We found that the fraction of CD4+CD28null cells proved to be predictive on outcome in CHF-patients presenting with AF. Our results might indicate a potential role of CD4+CD28null cells in the pathogenesis of AF which needs to be confirmed in future studies. Supplementary Material to this article is available online at www.thrombosis-online.com.


  • Risk of arrhythmic death in ischemic heart disease: a prospective, controlled, observer‐blind risk stratification over 10 years

    by Thomas Pezawas, André Diedrich, David Robertson, Robert Winker, Bernhard Richter, Li Wang, Herwig Schmidinger

    Background: Risk of arrhythmic death is considered highest in ischemic heart disease with severe left ventricular ejection fraction (LVEF) reduction. Non‐invasive testing should improve decision‐making of prophylactic defibrillator (ICD) implantation.Design: We enrolled 120 patients with ischemic heart disease and LVEF < 50% and 30 control subjects without ischemic heart disease and normal LVEF. An initial assessment, a second assessment after 3 years and a final follow‐up comprised of pharmacological baroreflex testing (BRS), short‐term spectral [low‐frequency (LF) to high‐frequency (HF) ratio] and long‐term time‐domain analysis of heart rate variability (SDNN), exercise Microvolt T‐wave alternans (MTWA) and others.Results: The median follow‐up was 7·5 years. Resuscitated cardiac arrest and arrhythmic death due to ventricular arrhythmias ≥ 240/min was observed in 18% and 15% of patients, respectively. Cardiac death was observed in 28% of patients. The incidence of arrhythmic death and resuscitated cardiac arrest was identical in patients with ischemic heart disease with LVEF < 30% and ≥ 30%. No significant difference between subgroups with LVEF of < 30%, 30–39% and ≥ 40% was found either. MTWA, BRS, SDNN and LF to HF ratio failed to identify patients at risk of arrhythmic death in a multiple regression model.Conclusions: Ischemic heart disease patients with LVEF < 30% and ≥ 30% face the same risk of arrhythmic death. Stratification techniques fail to identify high‐risk patients. Therefore, the current practice to constrain prophylactic ICDs to patients with severely reduced LVEF seems to be insufficient.


  • Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure

    by Lorenz Koller, Bernhard Richter, Max-Paul Winter, Patrick Sulzgruber, Christos Potolidis, Florian Liebhart, Deddo Mörtl, Rudolf Berger, Georg Goliasch, Irene Lang, et al.


  • Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction

    by Lorenz Koller, Marcus E. Kleber, Vincent M. Brandenburg, Georg Goliasch, Bernhard Richter, Patrick Sulzgruber, Hubert Scharnagl, Günther Silbernagel, Tanja B. Grammer, Graciela Delgado, et al.

    Background—: Strategies to improve risk prediction are of major importance in patients with heart failure (HF). Fibroblast growth factor 23 (FGF-23) is an endocrine regulator of phosphate and vitamin D homeostasis associated with an increased cardiovascular risk. We aimed to assess the prognostic effect of FGF-23 on mortality in HF patients with a particular focus on differences between patients with HF with preserved ejection fraction and patients with HF with reduced ejection fraction (HFrEF). Methods and Results—: FGF-23 levels were measured in 980 patients with HF enrolled in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study including 511 patients with HFrEF and 469 patients with HF with preserved ejection fraction and a median follow-up time of 8.6 years. FGF-23 was additionally measured in a second cohort comprising 320 patients with advanced HFrEF. FGF-23 was independently associated with mortality with an adjusted hazard ratio per 1-SD increase of 1.30 (95% confidence interval, 1.14–1.48; P P =0.043). External validation confirmed the significant association with mortality with an adjusted hazard ratio per 1 SD of 1.23 (95% confidence interval, 1.02–1.60; P =0.027). FGF-23 demonstrated an increased discriminatory power for mortality in addition to N-terminal pro–B-type natriuretic peptide ( C -statistic: 0.59 versus 0.63) and an improvement in net reclassification index (39.6%; P <0.001). Conclusions—: FGF-23 is independently associated with an increased risk of mortality in patients with HFrEF but not in those with HF with preserved ejection fraction, suggesting a different pathophysiologic role for both entities.


  • Radiofrequency catheter ablation can be performed with high success rates and very low complication rates in children and adolescents

    by Andreas Hanslik, Azra Mujagic, Elisabeth Mlczoch, Heinz Gössinger, Marianne Gwechenberger, Bernhard Richter, Manfred Marx, Sulaima Albinni

    Radiofrequency catheter ablation is a standard treatment for tachyarrhythmia in children. Recently, several centres using cryoenergy for ablation have reported high success and low complication rates, but an increased risk of recurrence of arrhythmia. The aim of this study was to report success, complications and recurrence rates for radiofrequency catheter ablation in children under current conditions.